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Summary
 
The identification of molecules that regulate human hematopoietic stem cells has focused
mainly on cytokines, of which very few are known to act directly on stem cells. Recent studies
in lower organisms and the mouse have suggested that bone morphogenetic proteins (BMPs)
may play a critical role in the specification of hematopoietic tissue from the mesodermal germ
layer. Here we report that BMPs regulate the proliferation and differentiation of highly purified
primitive human hematopoietic cells from adult and neonatal sources. Populations of rare
CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 stem cells were isolated from human hematopoietic tissue and were found
to express the BMP type I receptors activin-like kinase (ALK)-3 and ALK-6, and their down-
stream transducers SMAD-1, -4, and -5. Treatment of isolated stem cell populations with solu-
ble BMP-2, -4, and -7 induced dose-dependent changes in proliferation, clonogenicity, cell
surface phenotype, and multilineage repopulation capacity after transplantation in nonobese di-
abetic/severe combined immunodeficient (NOD/SCID) mice. Similar to transforming growth
factor 
 
b
 
, treatment of purified cells with BMP-2 or -7 at high concentrations inhibited prolif-
eration yet maintained the primitive CD34
 
1
 
CD38
 
2
 
 phenotype and repopulation capacity. In
contrast, low concentrations of BMP-4 induced proliferation and differentiation of CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells, whereas at higher concentrations BMP-4 extended the length of time that
repopulation capacity could be maintained in ex vivo culture, indicating a direct effect on stem
cell survival. The discovery that BMPs are capable of regulating repopulating cells provides a
new pathway for controlling human stem cell development and a powerful model system for
studying the biological mechanism of BMP action using primary human cells.
Key words: hematopoiesis • stem cells • bone morphogenetic proteins • ex vivo • 
xenotransplantation
 
K
 
nowledge of specific factors that regulate adult murine
and human blood stem cells is poor and has been
mainly limited to cytokines (1–3). Recent work using de-
velopmental systems has shown that mesodermal precursors
can be induced to differentiate into hematopoietic cells,
thereby giving rise to the earliest blood stem cells (4–9).
For example, cells purified from murine tissue that differ-
entiate from the ventral mesoderm, such as the aorta-
gonad-mesonephros and fetal liver, have been isolated and
shown to contain stem cells capable of multilineage he-
matopoietic repopulation (10, 11). These circulating stem
cells seed the embryonic rudiments of blood-forming tissue
to establish hematopoiesis. Analysis using developmental
models of lower organisms have identified soluble and/or
paracrine growth factors (GFs)
 
1
 
 that induce hematopoietic
tissue from ventral mesoderm (12, 13). The majority of
these factors are members of the TGF-
 
b
 
 superfamily of se-
creted polypeptide GFs (14, 15).
TGF-
 
b
 
 itself is a potent inhibitor of cell cycle progres-
sion of murine blood stem cells and primitive human long-
term culture initiating cells (LTC-ICs) detected using in
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Abbreviations used in this paper:
 
 ALK, activin-like kinase; BM, bone mar-
row; BMP, bone morphogenetic protein; CB, cord blood; CFC, colony-
forming cell; GF, growth factor; Lin, lineage; LTC-IC, long-term culture
initiating cell; M-PB, mobilized peripheral blood; NOD, nonobese dia-
betic; RT, reverse transcription; SRC, SCID-repopulating cell. 
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vitro assays (16, 17). Treatment of quiescent LTC-ICs with
neutralizing antibody against TGF-
 
b
 
 can induce cell cycle
entry (18). Moreover, TGF-
 
b
 
 is also secreted by immature
human hematopoietic cells, suggesting that a TGF-
 
b
 
 auto-
regulatory loop is an important component of regulation in
these primitive cells (19, 20). However, TGF-
 
b 
 
is the pro-
totype of a large family of cytokines that includes the TGF-
 
b
 
s, activins, inhibins, and bone morphogenetic proteins
(BMPs) (21). This family exerts a wide range of biological
responses such as cell growth, apoptosis, and differentiation
in a variety of cell types, including potent responses in pat-
terning during embryonic development (22). One member
of the BMP subfamily, BMP-4, has been shown to be a
potent ventralizing factor and can induce hematopoietic
tissue in 
 
Xenopus
 
 and differentiation of mouse embryonic
stem cells into hematopoietic lineages (23). BMP-4 and the
transcription factor GATA-2 can function in two adjacent
germ layers, mesoderm and ectoderm, respectively, to par-
ticipate in blood cell formation during embryogenesis (9,
13). This observation suggests that this subfamily of BMPs
may play a role in the development of primitive hemato-
poiesis. In humans, BMPs are expressed in adult human
bone marrow (BM) and are essential in bone remodeling
and growth (24). However, the ability of BMPs to con-
tinue to play a role in regulating blood stem cells once the
tissue has committed to the hematopoietic lineage, or to
play any direct role in adult and neonatal human stem cells,
is unknown.
The TGF-
 
b
 
 family of molecules signal through two
serine kinase receptors and a family of intracellular signal
transducers termed SMADs (25, 26). Soluble TGF-
 
b
 
 and
related molecules induce formation of heterodimeric com-
plexes of type II and type I transmembrane kinase receptors
(27). Within this complex, the type II kinase transphosphor-
ylates the type I receptor, which transmits downstream sig-
nals to receptor-related SMADs, thereby specifying the na-
ture of the biological response to ligand. Phosphorylation of
receptor-regulated SMADs induces association in the cyto-
plasm with a common mediator of SMADs, called SMAD-4
(28, 29). This heteromeric complex then moves into the
nucleus to regulate gene expression (26). Introduction of ho-
mologous SMAD proteins from human or mouse into frog
embryos mimics the effects of TGF-
 
b
 
 activation in the in-
duction of mesodermal specification, illustrating the phylo-
genetic conservation of these molecules (25, 30). Moreover,
recent evidence in humans indicates that disregulation of
the SMAD molecules can affect normal growth, leading to
neoplastic hematopoiesis (31).
Most of the studies aimed at understanding the potential
biological role of BMPs in hematopoietic tissue have relied
almost exclusively on model systems involving lower or-
ganisms and in vitro systems (32, 33). Therefore, there is a
great need for a more biologically relevant model system to
determine the role and function of BMPs in human hema-
topoietic development. In this study, to ascertain whether
BMPs are capable of regulating primitive blood cells, we
have used a highly purified fraction of human hematopoie-
tic tissue enriched for human repopulating stem cells (34,
 
35). These human repopulating cells can be assayed by
transplantation into nonobese diabetic (NOD)/SCID mice
(36, 37). This repopulating cell, termed SCID-repopulating
cell (SRC), is capable of extensive proliferation and multi-
lineage engraftment (34, 36). Cell purification and retrovi-
ral gene-marking studies demonstrated that the SRCs are
the most primitive cell type detected in the human stem
cell hierarchy and are biologically distinct from most cells
detected using in vitro assays, including colony-forming
cells (CFCs) and LTC-ICs (34, 35, 38). Here, we report
that BMP receptors activin-like kinase (ALK)-3 and -6 to-
gether with the signal transducers SMAD-1, -4, and -5 are
expressed by highly purified CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells iso-
lated from various human hematopoietic tissues. The addi-
tion of human BMP-2, -4, and -7 into previously designed
serum-free ex vivo cultures (38) resulted in alterations in
the proliferation, differentiation, and number of clonogenic
progenitors within the CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 population.
Among these ligands, BMP-4 had a regulatory function
distinct from BMP-2 and -7, and was capable of acting
on rare repopulating SRCs. These data demonstrate that
BMPs modulate the developmental program of human
stem cells and provide a novel model system to further un-
derstand the mechanism of BMP action within primary hu-
man cells.
 
Materials and Methods
 
Human Cells.
 
Samples of human cord blood (CB) were ob-
tained from placental and umbilical tissues and diluted (1:3) in
IMDM (GIBCO BRL). The mononuclear cells were collected by
centrifugation on Ficoll-paque (Amersham Pharmacia Biotech).
 
Cell Purification.
 
CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells were collected us-
ing our standard protocol (22, 23). CB cells were first enriched
for CD34
 
1
 
 cells by negative selection using a cocktail of lineage
(Lin) antibodies and the StemSep device as described by the manu-
facturer (Stem Cell Technologies, Inc.). These cell fractions were
then stained with anti–human CD34-FITC and anti–human
CD38–PE (Becton Dickinson Immunocytometry Systems), ana-
lyzed, and sorted on a FACStar
 
Plus
 
™ (Becton Dickinson). The
sorting gates used were similar to those shown previously (34, 38).
Data acquisition and analysis were performed using CELLQuest™
software (Becton Dickinson).
 
Reverse Transcription PCR Analysis.
 
Purified cells were col-
lected after sorting in 500-
 
m
 
l tubes, and mRNA was extracted
from 1,000 cells for each PCR reaction using a purification kit
(Amersham Pharmacia Biotech). The mRNA was reverse tran-
scribed into cDNA by standard methods using Superscript II
(GIBCO BRL) as the reverse transcriptional enzyme. PCR was
performed for the detection of transcripts using a Perkin-Elmer
9700 cycler with the indicated specific primers for 40 cycles.
Primer sequences used for transcript detection for SMADs and
ALK receptor were as follows: SMAD-1F, 5
 
9
 
-CGAATGCCTTA-
GTGACAG-3
 
9
 
, and SMAD-1R, 5
 
9
 
-GAGGTGAACCCATTT-
GAG-3
 
9
 
; SMAD-4F, 5
 
9
 
-AGGTGAAGGTGATGTTTG-3
 
9
 
, and
SMAD-4R, 5
 
9
 
-GCTATTCCACCTACTGAT-3
 
9
 
; SMAD-5F,
5
 
9
 
-TGTTGGTGGAGAGGTGTA-3
 
9
 
, and SMAD-5R, 5
 
9
 
-AGA-
TATGGGGTTCAGAGG-3
 
9
 
; ALK-3F, 5
 
9
 
-ACCATCGGAG-
GAGAAACT-3
 
9
 
, and ALK-3R, 5
 
9
 
-CTGCTGCGCTCATTT-
ATC-3
 
9
 
; ALK-6F, 5
 
9
 
-AAGTTACGCCCCTCATTC-3
 
9
 
, and
ALK-6R, 5
 
9
 
-TGATGTCTTTTGCTCTGC-3
 
9
 
. 
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Clonogenic Progenitor Assays.
 
Human clonogenic progenitors
were assayed under standard conditions as shown previously,
which included the addition of 10% 5637 conditioned medium as
a source of cytokines (38). In brief, 100–500 purified cells were
plated in methylcellulose cultures aliquoted in 1-ml vol in 35-mm
suspension culture dishes and incubated at 37
 
8
 
C. After 10–14 d, clo-
nogenic progenitors were scored according to standard criteria (38).
 
Liquid Suspension Cultures.
 
CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells were in-
cubated in serum-free conditioned medium shown previously to
maintain primitive human populations (38). In brief, conditioned
medium is comprised of 50 
 
m
 
l of IMDM supplemented with 1%
BSA (Stem Cell Technologies, Inc.), 5 
 
m
 
g/ml of human insulin
(Humulin R; Eli Lilly and Co.), 100 
 
m
 
g/ml of human transferrin
(GIBCO BRL), 10
 
2
 
4
 
 M 
 
b
 
-mercaptoethanol, and GFs. GF cock-
tail was used at final concentrations of 300 ng/ml of stem cell fac-
tor (SCF; Amgen) and Flt-3 (Immunex), 50 ng/ml of G-CSF
(Amgen), and 10 ng/ml of IL-3 (Amgen) and IL-6 (Amgen).
Cells were cultured in flat-bottomed suspension wells of 96-well
plates (Nunc), incubated for the appropriate times as indicated, at
37
 
8
 
C and 5% CO
 
2
 
, and 50 
 
m
 
l of fresh GF cocktail was added to
each well every other day. Mesodermal factors were added to ob-
tain final concentrations as indicated. Individual factors were ob-
tained from the following sources: TGF-
 
b
 
1 and TGF-
 
b
 
1–3 neu-
tralizing antibody (R&D Systems), BMP-2 (gift from Dr. Vicki
Rosen, Genetics Institute, Cambridge, MA), BMP-4 (gift from
Dr. Steve Neben, Genetics Institute), and BMP-7 (gift from Dr.
Kuber Sampath, Creative Biomolecules, Inc., Boston, MA).
 
Transplantation of Purified Cells into NOD/SCID Mice.
 
Cells
were transplanted by tail vein injection into sublethally irradiated
NOD/LtSz-scid/scid (NOD/SCID) mice (375-cGy 
 
137
 
Cs) accord-
ing to our standard protocol (36, 39). In all cases, cells were co-
transplanted with irradiated nonrepopulating CD34
 
2
 
Lin
 
1
 
 cells as
accessory cells (34, 38). Mice were killed 8 wk after transplantation,
and BM cells were collected from femurs, tibiae, and iliac crests.
 
Analysis of Human Cell Engraftment.
 
High molecular weight
DNA was isolated from the BM of transplanted mice, and the
percentage of human cells was determined by probing with a hu-
man chromosome 17–specific 
 
a
 
-satellite probe as described pre-
viously (36, 39). The level of human cell engraftment was quanti-
fied by visual inspection of film developed from Southern blot by
comparing the characteristic 2.7-kb band with human/mouse
DNA mixture controls (limit of detection, 0.05% human DNA)
that provided a linear signal response. In some cases, BM of trans-
planted mice was analyzed by staining with human panleukocyte
marker CD45 to detect the presence of human hematopoietic
cells using the FACScan
 
®
 
 as described previously (34, 36, 38, 39).
Two- or three-color flow cytometric analysis was performed as
shown previously to ensure that human engrafting cells contained
multiple lineages (data not shown).
 
Statistical Analysis.
 
The data were analyzed by the unpaired,
two-tailed Student’s 
 
t
 
 test assuming a Gaussian distribution (para-
metric test) using Prism
 
®
 
 software, version 2.0 (GraphPad).
 
Results
 
Expression of SMAD Signaling Molecules and BMP Recep-
tors in Primitive Human Hematopoietic Populations.
 
TGF-
 
b
 
receptors have previously been shown to be expressed on
highly purified primitive hematopoietic populations in
which soluble TGF-
 
b
 
 is capable of regulating proliferation
and progenitor cell content (19, 20). Our previous studies
demonstrated that highly purified SRCs derived from both
human CB and BM were found in the fraction of CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells (34, 35, 38). The type I BMP receptors
ALK-3 and ALK-6 are capable of binding BMPs in the
absence of type II receptors, and it has been suggested
that these receptors may be capable of ligand selection and
may be specific for BMPs (15, 40). Reverse transcription
(RT)-PCR analysis demonstrated that both ALK-3 and -6
are expressed in primitive CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells isolated
from human CB and BM tissue (Fig. 1 A). Detection of
ALK-3 and -6 expression in BM samples was more difficult
compared with CB-derived primitive populations at similar
RT-PCR conditions, suggesting lower expression in BM
versus CB. SMAD-1 and -5 are restricted for BMP signal-
ing, whereas SMAD-4 is a shared mediator of TGF-
 
b
 
 sig-
naling, and acts as a common partner with pathway-specific
SMADs (25, 26). Purified CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells isolated
from human CB, BM, mobilized peripheral blood (M-PB),
and human BM-derived stroma express SMAD-1 and -5
transcripts (Fig. 1 B). SMAD-4 expression was found in all
Figure 1. Expression of BMP receptors and SMADs in primitive he-
matopoietic tissue derived from human sources. RT-PCR reactions were
performed on human CD341CD382Lin2 cells from CB (n 5 4), BM (n 5
2), M-PB (n 5 2), and stromal cells (n 5 2) as indicated for (A) BMP re-
ceptors ALK-3 and -6, and (B) human SMAD-1, -4, and -5. RT-PCR
was performed on whole human fetus sample as a positive control for the
reaction. 
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sources of primitive cells, but was more easily detected in
BM (n 5 2) than in CB samples (n 5 4) and was barely de-
tectable in M-PB (n 5 2). In summary, transducers of the
BMP signaling pathway are expressed in primitive subfrac-
tions of both embryonic and adult human hematopoietic
tissue, suggesting that candidate human stem cell popula-
tions have the capability of responding to BMPs.
Effect of BMPs on the Proliferation and Differentiation of Hu-
man CD341CD382Lin2 Cells. The proliferative response
of CD341CD382Lin2 cells in response to BMP treatment
was determined by comparing the number of cells obtained
after 3 d of culture in the presence or absence of BMPs to
the number originally seeded at day 0 (Fig. 2 A). Cells were
seeded in ex vivo culture conditions with serum-free media
(control SF, which we had previously designed to allow for
the expansion of primitive human blood cells [38]) and
were compared with cultures in which TGF-b, BMP-2,
-4, -7, or 5% serum was added (Fig. 2 A). The addition of
TGF-b inhibited the proliferative response seen in control
SF conditions by 80% but did maintain the number of cells
initially incubated, whereas TGF-b neutralizing antibody
had no additional effect on total cell number compared
with control conditions (Fig. 2 A). Consistent with effects
on cell growth, treatment with TGF-b maintained the
number of progenitors capable of producing CFCs after 3 d
of culture, whereas TGF-b antibody had no effect on CFC
capacity (Fig. 2 B). BMP-2 and -7 had a modest effect on
cell growth at concentrations of 5 ng/ml; however, at
higher concentrations (50 ng/ml) both BMP-2 and -7
treatment inhibited cell proliferation similar to TGF-b.
The inhibitory growth effect of BMP-2 and -7 is consistent
with decreased CFC content of treated cultures. BMP-2
and -7 decreased the CFC capacity of CD341CD382Lin2
cells in a dose-responsive manner; however, at 5 ng/ml
BMP-7 was less effective than BMP-2 (Fig. 2 B). In the
cases of TGF-b, BMP-2, and BMP-7, changes in total
cell number correlated with changes in CFC content but
did not selectively alter the specific type of progenitor
detected, demonstrating that BMPs do not affect lineage
commitment. This suggests that BMP-2 and -7 are capable
of modulating proliferation of primitive CD341CD382
Lin2 cells in a manner that does not alter the developmental
program and differentiation capacity of primitive cell popu-
lations. Addition of 5% serum caused a massive proliferative
response (Fig. 2 A) along with a dramatic decrease in the
number of cells capable of producing progenitors, indicative
of differentiation induction (Fig. 2 B).
Treatment of CD341CD382Lin2 cells with BMP-4 in-
voked a unique response compared with TGF-b, BMP-2,
and BMP-7. The addition of BMP-4 at 5 ng/ml inhibited
the cell growth of CD341CD382Lin2 cells, in contrast to
the effects observed using BMP-2 and -7 at similar concen-
trations (Fig. 2 A). Increasing BMP-4 concentrations to 50
ng/ml was toxic to CD341CD382Lin2 cells (data not
shown). Concentrations of 25 ng/ml of BMP-4 did not al-
ter cell viability and were capable of inducing an increase in
cell number over control SF conditions (Fig. 2 A). The
ability of CD341CD382Lin2 cells to produce CFCs in re-
sponse to BMP-4 was also dose dependent. Although 5 ng/ml
of BMP-4 inhibited proliferation of CD341CD382Lin2
cells, CFC content was only slightly decreased compared
with control, resulting in increased frequency. CD341
CD382Lin2 cells treated with 25 ng/ml of BMP-4 dramat-
ically expanded CFCs compared with control SF condi-
tions (Fig. 2 B). These data indicate that members of the
Figure 2. Effect of ex vivo culture on the total cell number and num-
ber of clonogenic progenitors present after in vitro culture of
CD341CD382Lin2 cells in the presence of BMPs. (A) Purified
CD341CD382Lin2 cells were counted and seeded (700–1,000) in wells
containing serum-free media or with the addition of factors indicated at
day 0. Cells were harvested from individual wells after 3 d of culture and
counted, and the mean fold increase in absolute cell number was calcu-
lated (n 5 4). (B) An aliquot of 100–300 CD341CD382Lin2 cells was
plated in progenitor cell assays at the initiation of ex vivo cultures (day 0),
and the frequency of progenitors was calculated. Similar cell doses were
plated from wells harvested after 3 d of cultures containing the various
factors indicated, and the mean fold increase in number of CFCs was cal-
culated compared with day 0 (n 5 3). Values are the mean 6 SEM of de-
terminations in four and three separate culture samples for cell number
and clonogenic progenitors, respectively. *P , 0.05, **P , 0.01 indicate
statistically significant differences from controls.1143 Bhatia et al.
TGF-b family, including those in the BMP subfamily, are
capable of modulating proliferation and differentiation of
primitive human blood cells and that the effects are specific
to the dose and subtype of BMP ligand.
Phenotypic Analysis of Human CD341CD382Lin2 Cells
Treated with BMPs. To determine whether BMP treat-
ment affected the differentiation program of primitive hu-
man CD341CD382Lin2 cells, cultures were analyzed by
flow cytometry for changes in CD34 and CD38 expression
(Fig. 3). Similar to that shown previously (38), control SF
cultures induced modest differentiation of CD341CD382
Lin2 cells into CD341CD381 cells (Fig. 3 A), whereas the
addition of 5% serum induced a differentiation response as
demonstrated by the acquisition of CD38 and loss of CD34
expression. Both TGF-b and TGF-b neutralizing antibody
had little effect on the CD341CD382 phenotype and re-
mained similar to control cultures (Fig. 3 A).
Members of the BMP subfamily caused changes in
CD341CD382 phenotype compared with control SF con-
ditions (Fig. 3 A). At concentrations of 5 ng/ml, both
BMP-2 and -7 had a potent differentiation effect on
CD341CD382Lin2 cells as demonstrated by the acquisi-
tion of CD38; however, the population remained relatively
immature since the cells were all CD34 positive. At higher
concentrations of 50 ng/ml, both BMP-2 and -7 main-
tained equivalent numbers of CD341CD382 cells com-
pared with control SF conditions (Fig. 3 B). Phenotypic
analysis of CD341CD382Lin2 cells after treatment with
BMP-4 was distinct from that observed for BMP-2 and -7.
At low doses, BMP-4 induced a complete differentiation of
CD341CD382 cells into CD341CD381 cells, whereas at
higher doses two populations developed: one that had dif-
ferentiated and one that maintained a primitive phenotype
(Fig. 3 B). To further investigate the unique response of
CD341CD382Lin2 cells to BMP-4, phenotypic analysis
was extended to 6 d of ex vivo culture (Fig. 4). Parallel cul-
tures of CD341CD382Lin2 cells incubated in control SF
conditions for 6 d differentiated into CD341CD381 cells,
similar to the differentiation response seen when low con-
centrations of 5 ng/ml of BMP-4 were added (Fig. 4). In
contrast, the high concentration of BMP-4 treatment re-
sulted in the maintenance of a significant proportion of
primitive CD341CD382 cells. These changes in the phe-
notype of CD341CD382Lin2 cells in response to BMP
treatment illustrate that these factors are capable of modu-
lating the developmental program of primitive subsets of
CD341 cells. Consistent with effects on proliferation and
CFC capacity, BMP-4 is capable of inducing distinct dose-
Figure 3. Comparative analysis of CD34 and CD38 expression of highly purified CD341CD382Lin2 cells after 4 d of culture in the presence of
BMPs. A representative experiment (n 5 3) of CD34 and CD38 cell surface expression performed on initially purified CD341CD382Lin2 cells after 4 d
of culture in serum-free conditions or with the addition of factors as indicated. The entire contents of individual wells were collected at 4 d, stained with
mAbs, and analyzed using flow cytometric analysis.1144 Bone Morphogenetic Proteins Regulate Human Blood Stem Cells
dependent effects on the differentiation program of human
CD341CD382Lin2 cells compared with other members of
the TGF-b superfamily tested.
Role of BMPs on Human Hematopoietic Cells Capable of Re-
population (SRCs). Using the SRC assay, we have previ-
ously demonstrated that serum-free ex vivo cultures were
the only conditions capable of maintaining pluripotent re-
populating cells for as long as 4 d before transplantation
(38). However, even under these conditions, no SRCs
were present after 9 d although CFCs and CD341 cells ex-
panded enormously during this time period. These previ-
ous results indicated that even these optimized cultures had
limited ability to expand or even maintain SRCs. Accord-
ingly, we have assessed the effect of BMP treatment on
SRC maintenance and expansion. Wells were seeded ini-
tially with 700–1,000 CD341CD382Lin2 cells in control
SF conditions representing 1 or 2 SRCs. BMPs were added
as indicated, and the entire contents of each well were then
transplanted into NOD/SCID mice at 2, 4, and 6 d. Hu-
man cell engraftment was determined 8 wk after transplant,
and results are summarized in Table I.
The frequency of mice engrafted after transplantation of
cells cultured for 2 d in ex vivo cultures was similar in all
treatment groups, with the exception of cultures contain-
ing 5% serum, which were unable to sustain SRCs after 2
and 4 d (Table I). The addition of serum caused the major-
ity of CD341CD382 cells to acquire CD38 and/or lose
CD34 cell surface expression after 4 d (Fig. 2). This differ-
entiation shift suggests that the SRCs have most likely un-
dergone differentiation into more mature cells that no
longer repopulate. However, since primitive CD341CD382
cells were present in serum-containing cultures, the loss of
SRCs is most likely associated with maturation that oc-
curred independent of CD38 acquisition. Similar results
have also been obtained in a separate study examining the
loss of SRCs during culture for retroviral transduction, and
demonstrate that there is dissociation between phenotype
and function as a consequence of downregulation of CD38
in differentiated cells after culture in serum (our unpub-
lished data). All mice transplanted with purified cells
cultured for 4 d in control SF conditions were repopulated
(100%). However, cultures containing ligands at con-
centrations having inhibitory effects on cell growth and
CFC capacity, such as TGF-b, 50 ng/ml of BMP-2 and -7,
Figure 4. Analysis of CD34 and CD38
expression of highly purified CD341
CD382Lin2 cells after 6 d of culture in the
presence of BMP-4. A representative exper-
iment (n 5 3) of CD34 and CD38 cell sur-
face expression performed on initially puri-
fied CD341CD382Lin2 cells after 6 d of
culture in serum-free conditions or with the
addition of BMP-4 at 5 or 25 ng/ml. The
entire contents of individual wells were col-
lected at 6 d, stained with mAbs, and ana-
lyzed using flow cytometric analysis.
Table I. Analysis of SRCs after 2, 4, and 6 d of Ex Vivo Culture in the Presence of BMPs
Treatments
Day 2 Day 4 Day 6
No. pos No. neg % positive No. pos No. neg % positive No. pos No. neg % positive
Control SF 7 0 100 10 1 100 0 9 0
a–TGF-b (50 ng/ml) 1 1 50 2 0 100 1 3 25
TGF-b (400 pM) 3 0 100 3 7 30 0 2 0
BMP-2 (5 ng/ml) 7 0 100 6 0 100 1 3 25
BMP-2 (50 ng/ml) ND 0 4 4 ND
BMP-7 (5 ng/ml) 6 0 100 7 0 100 0 5 0
BMP-7 (50 ng/ml) ND 1 3 25 0 4 0
BMP-4 (5 ng/ml) ND 1 2 33 0 4 0
BMP-4 (25 ng/ml) 1 0 100 7 0 100 5 1 83
5% FCS 0 4 0 0 3 0 ND
Summary of the frequency of engrafted mice after transplantation of CD341CD382Lin2 cells after ex vivo culture. The human cell engraftment in
the BM of 121 mice transplanted with CD341CD382Lin2 cells expanded for 2, 4, and 6 d was determined by DNA extraction 8 wk after transplant
and hybridized with a human chromosome 17–specific a-satellite probe as shown previously. The percentage of human engraftment in the BM of
positive mice ranged between 0.1 and 1%.
pos, positive; neg, negative.1145 Bhatia et al.
and 5 ng/ml of BMP-4 (Fig. 2, A and B), all resulted in a
decrease in the frequency of engrafted animals, suggesting a
loss of SRCs during culture (Table I). In contrast, but con-
sistent with mitogenic responses detected by cell growth
and CFC capacity, the addition of TGF-b neutralizing anti-
body, 5 ng/ml of BMP-2 and -7, or 25 ng/ml of BMP-4
allowed for the maintenance of SRCs after 4 d of culture as
indicated by 100% engraftment frequency in transplanted
animals.
Since all mice transplanted with control SF cultures at 4 d
of culture were also engrafted, it was difficult to determine
whether the addition of BMPs was affecting human repop-
ulating cells. By using similar techniques of limiting dilu-
tion analysis employed in our previous studies (34, 38), we
compared cultures treated with BMPs or TGF-b to assess
effects on the number of SRCs at day 4; no significant dif-
ferences in the frequency of SRCs were found (data not
shown). To determine whether BMPs were capable of af-
fecting the survival of SRCs, cultures were extended for up
to 6 d. After 6 d of ex vivo culture, SRCs could not be de-
tected under SF conditions. In contrast, one out of four
cultures containing TGF-b neutralizing antibody or 5 ng/ml
of BMP-2 contained repopulating cells. The most dramatic
effect was seen in cultures containing 25 ng/ml of BMP-4,
where as few as 700 CD341CD382Lin2 cells cultured un-
der these conditions for 6 d were capable of engrafting 5
out of 6 mice (83%; Table I). The percentage of human
chimerism in the BM of all positive mice shown in Table I
ranged between 0.1 and 1%. These results are consistent
with our previous studies in which transplantation of one
SRC enriched in purified CD341CD382 cells at limiting
dose allowed for similar levels of human engraftment (34,
38). Further extension of ex vivo cultures containing 25
ng/ml of BMP-4 to 8 d resulted in the loss of SRCs (data
not shown). These data demonstrate the novel role of
BMPs in regulating the repopulating function of primitive
human hematopoietic cells and demonstrate that BMP-4
acts as a survival factor for candidate human stem cells.
Discussion
The development of serum-free ex vivo culture systems
together within xenogenic transplant systems that are capa-
ble of detecting human repopulating cells has provided a
method for the further identification of factors regulating
the developmental program of candidate human stem cells
(SRCs [38]). In this report, we provide the first evidence
for the role of BMPs in the modulation of the develop-
mental program of primitive subfractions of CD341CD382
Lin2 cells that contain SRCs. Treatment with BMP-2, -4,
and -7 resulted in dose-dependent effects on the growth,
differentiation, and repopulating function of CD341
CD382Lin2 cells. Evidence of the regulatory role of BMPs
was best demonstrated by BMP-4 treatment. At low con-
centrations of BMP-4, rapid differentiation was seen as well
as loss of SRCs. At high doses, some differentiation oc-
curred, but a significant proportion of primitive CD341
CD382Lin2 cells remained and more importantly SRCs
were present. BMP-4 was capable of extending the dura-
tion of stem cell activity in culture for an additional 2 d in
comparison with all other previously optimized conditions
using cytokines believed to act on primitive blood cells.
Thus, BMP-4 is acting as a survival factor, preserving stem
cell function under conditions that normally lead to stem
cell loss.
The expression of pathway-restricted SMAD-1 and -5,
together with expression of BMP receptors ALK-3 and -6,
suggest that the mechanism of BMP action is due to the
specific activation of the BMP pathway that is distinct from
TGF-b signaling. In addition, BMP-2 and -4 normally in-
duce similar cellular responses, and therefore the differential
effects of BMP-2 compared with BMP-4 on primitive he-
matopoietic tissue shown here are unique, and remain to
be tested in other species and tissue types using similar in
vivo model systems for primary tissue. This unique re-
sponse of human blood stem cells to BMP-4 ligand may be
due to a previously unreported receptor and/or inhibitory
molecule mediating BMP-4 signals that is expressed by this
population of rare blood cells. Alternatively, the divergent
effect of BMP-2 and -4 may not be at the receptor level
and may be due to the synergistic effects of BMP-4 with
other cytokines used in this ex vivo culture system, which
do not have overlapping effects on BMP-2–specific path-
ways. The differential response of BMP-2 and -4 may not
diverge at the level of intercellular signaling in individual
cells, but could be due to an intrinsic heterogeneity of
BMP receptor expression within the cells that comprise this
population. At day 3 and 6 of ex vivo culture, BMP-4 was
capable of inducing a differentiation response shown by the
acquisition of CD38, but also of maintaining the primitive
phenotype of a potentially distinct subset of CD341CD382
cells. These results are most easily interpreted by the exist-
ence of two differentially responsive populations that are
heterogeneous at the level of BMP binding proteins. Evi-
dence from other gene transfer and cell purification studies
has already suggested that CD341CD382Lin2 cells are het-
erogeneous and that there is a hierarchy of stem cells
within this cell fraction (35). To address this possibility, it
would be necessary to develop flow cytometric methods to
detect subpopulations within CD341CD382Lin2 fractions
using fluorochrome-conjugated BMP ligands or antibodies
to BMP receptors. Reagents to perform these experiments
are currently being developed.
The results reported here, together with studies using
other developmental systems, underscore the role of BMP-4
in primitive hematopoietic tissue and demonstrate that
BMPs continue to regulate blood development well after
tissue specification (13, 41). Thus, an entirely new avenue
remains to be explored to identify this new biological
mechanism of stem cell regulation. Moreover, ex vivo cul-
ture of human hematopoietic cells is a crucial component
of many therapeutic applications, including gene therapy,
tumor cell purging, and stem/progenitor cell expansion
(42), and therefore the identification of this novel class of
stem cell regulatory molecules opens the way to developing
these clinical applications. Since current ex vivo culture1146 Bone Morphogenetic Proteins Regulate Human Blood Stem Cells
systems for human blood cells are limited in their ability to
maintain stem cells in vitro (38, 42), the ability to extend
the period in which repopulating cells can be maintained in
culture with the addition of factors such as BMP-4 repre-
sents a significant advance in these systems. Based on the
novel role of this family of molecules in the regulation of
primitive hematopoietic tissue, this study establishes the
foundation for the use of these and other mesodermal regu-
lators in the manipulation of human stem cells in a clinical
setting.
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